Gregory R. Friberg's most recent trade in Biomarin Pharmaceutical Inc. - Registered Shares was a trade of 41,170 Stock Option (Right to Buy Common Stock) done . Disclosure was reported to the exchange on March 17, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Biomarin Pharmaceutical Inc | Gregory R. Friberg | EVP, Chief R&D Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Mar 2025 | 41,170 | 41,170 | - | - | Stock Option (Right to Buy Common Stock) | |
| Biomarin Pharmaceutical Inc | Gregory R. Friberg | EVP, Chief R&D Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Mar 2025 | 17,750 | 46,810 (0%) | 0% | 0 | Common Stock | |
| Biomarin Pharmaceutical Inc | Gregory R. Friberg | EVP, Chief R&D Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2024 | 49,850 | 49,850 | - | - | Stock Option (Right to Buy Common Stock) | |
| Biomarin Pharmaceutical Inc | Gregory R. Friberg | EVP, Chief R&D Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2024 | 21,190 | 21,190 (0%) | 0% | 0 | Common Stock | |
| Biomarin Pharmaceutical Inc | Gregory R. Friberg | EVP, Chief R&D Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2024 | 7,870 | 29,060 (0%) | 0% | 0 | Common Stock |